RLMD

Aug 7, 2026, 11:04 UTC

Relmada Therapeutics announced it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, targeting an investigational new drug application filing by the end of 2026.